Coherus BioSciences Inc.

0.89
-0.03 (-2.81%)
At close: Mar 18, 2025, 3:59 PM
0.88
-0.94%
After-hours: Mar 18, 2025, 07:59 PM EDT
-2.81%
Bid 0.87
Market Cap 102.95M
Revenue (ttm) 268.05M
Net Income (ttm) 28.62M
EPS (ttm) 0.25
PE Ratio (ttm) 3.55
Forward PE -77.73
Analyst Buy
Ask 0.89
Volume 1,577,031
Avg. Volume (20D) 2,188,262.4
Open 0.93
Previous Close 0.92
Day's Range 0.88 - 0.93
52-Week Range 0.66 - 2.64
Beta 0.93

About CHRS

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma ...

Industry Biotechnology
Sector Healthcare
IPO Date Nov 6, 2014
Employees 235
Stock Exchange NASDAQ
Ticker Symbol CHRS
Full Company Profile

Analyst Forecast

According to 4 analyst ratings, the average rating for CHRS stock is "Buy." The 12-month stock price forecast is $7, which is an increase of 688.02% from the latest price.

Stock Forecasts

Earnings Surprise

Coherus BioSciences has released their quartely earnings on Mar 10, 2025:
  • Revenue of $54.14M exceeds estimates by $10.26M, with -40.84% YoY decline.
  • EPS of -0.28 misses estimates by -0.15, with 54.84% YoY growth.
  • Next Earnings Release

    Coherus BioSciences Inc. is scheduled to release its earnings on May 8, 2025, during market hours.
    Analysts project revenue of ... Unlock content with Pro Subscription
    3 months ago
    +24.82%
    Coherus Biosciences shares are trading higher afte... Unlock content with Pro Subscription
    4 months ago
    +13.29%
    Coherus BioSciences shares are trading higher after the company reported better-than-expected Q3 financial results.